Insmed reported $-297127000 in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
DBV Technologies USD -39036000 16.89M Jun/2025
Dynavax Technologies USD -21594000 22.03M Mar/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Insmed USD -297127000 71.11M Jun/2025
Novartis USD 6.08B 739M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025